News from amgen inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

16:40 ET
Amgen Logo.

Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH™ Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia

 Amgen (NASDAQ: AMGN), The Familial Hypercholesterolemia Foundation and Stanford Medicine today announced the launch of the FIND (FLAG,...

Jan 27, 2015, 16:02 ET
Amgen Logo.

Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

 Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a supplemental New Drug Application...

Jan 27, 2015, 16:01 ET
Amgen Logo.

Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2014. Key results include: - For the fourth...

Jan 22, 2015, 16:01 ET
Amgen Logo.

Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results

 Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2014 financial results on Tuesday, Jan. 27, 2015,...

Jan 15, 2015, 16:01 ET
Amgen Logo.

Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer

Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix®...

Jan 12, 2015, 16:01 ET
Amgen Logo.

Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome

Amgen (NASDAQ: AMGN) and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen's...

Jan 08, 2015, 16:15 ET
Amgen Logo.

Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference

 Amgen (NASDAQ: AMGN) will present at the 33rd Annual J.P. Morgan Healthcare Conference at 9:30 a.m. PT on Tuesday, Jan. 13, 2015, at the...

Jan 05, 2015, 09:00 ET
Amgen Logo.

Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies

 Amgen (NASDAQ:AMGN) and Kite Pharma (NASDAQ:KITE) announced today that the two companies have entered into a strategic research collaboration...

Dec 17, 2014, 17:45 ET
Amgen Logo.

Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend

 Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015. The...

Dec 11, 2014, 16:01 ET
Amgen Logo.

Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial...

Dec 08, 2014, 21:00 ET
Amgen Logo.

Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

 Amgen (NASDAQ: AMGN) today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO™ (blinatumomab) for the...

Dec 08, 2014, 16:20 ET
Amgen Logo.

New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma

Amgen (NASDAQ: AMGN) today announced the initiation of a trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, in...

Dec 08, 2014, 14:47 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma

 Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced today results of the Phase 3 ASPIRE (CArfilzomib, Lenalidomide,...

Dec 08, 2014, 09:00 ET
Amgen Logo.

FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab)...

Dec 06, 2014, 13:00 ET
Amgen Logo

Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease

 Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager (BiTE®)...

Dec 03, 2014, 19:00 ET
Amgen Logo.

Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition

Amgen (NASDAQ: AMGN) will host a webcast investor meeting at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday,...

Dec 03, 2014, 16:45 ET

Actriz Adamari López y Amgen lanzan Quimioterapia: Mitos y Realidades sitio web y recursos en Español

Hoy Amgen (NASDAQ:AMGN) lanzo Quimioterapia: Mitos y Realidades, una extensión en Español de Chemotheraphy: Myths or Facts™,...

Dec 03, 2014, 16:30 ET
Amgen Logo.

Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources

Amgen (NASDAQ: AMGN) today launched Quimioterapia: Mitos y Realidades, a Spanish-language extension of the Chemotherapy: Myths or FactsTM awareness...

Dec 03, 2014, 15:48 ET
Amgen Logo

FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of BLINCYTO™ (blinatumomab) for the...

Nov 25, 2014, 16:01 ET
Amgen Logo.

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of...